Open Biosystems and Abcam Announce Partnership to Match Antibodies with Genetic Content
News Aug 09, 2007
Open Biosystems, Inc. and Abcam, Plc., announced that they have entered into an agreement under which Open Biosystems will sell Abcam's primary antibodies alongside Open's libraries of cDNA, ORF and shRNA clones. The agreement creates the world's most extensive resource of genetic content for the analysis of gene function.
Customers will be able to use the advanced gene search tool at Open's website to query by gene symbol or accession to bring up an index of all of the matched content available to study a gene. Matched products will be shipped together within 48 hours of order receipt.
Matt Baker, Executive VP of Business Development at Open, said, "Open Biosystems continues to enhance the value of genetic content available for academic and commercial scientists. The agreement with Abcam further enables researchers to have access to a comprehensive solution for functional gene analysis expressing a gene, knocking down a gene and detecting the gene product all from one provider."
Jonathan Milner, CEO of Abcam said, "We are delighted to sign this agreement with Open Biosystems. Abcam is recognized in the marketplace for the quality of our products and we are happy to provide Open Biosystems with a selection of our products for distribution alongside their comprehensive range of gene content analysis components. We are enthusiastic to be working alongside Open Biosystems, and I believe it will allow both companies to expand in this exciting part of the market.
Back in 2009, researchers identified a herd of Awassi sheep suffering from "day blindness". As that term implies, these sheep were blind during the day (in bright light) but could see at night, in low-light conditions. After identifying the genetic basis of this blindness, researchers have now successfully used gene therapy to restore their daytime vision.READ MORE